Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Azenta Inc. (AZTA) Insider Trading Activity

    Healthcare • Medical Instruments & Supplies • 3,300 employees

    Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

    Total Value

    $9,358,595.51

    Total Shares

    220,458

    Average Trade Value

    $283,593.80

    Most Active Insider

    Marotta John

    Total Activity: $4,024,014

    Largest Single Transaction

    $3,471,149

    by Marotta John on Nov 15, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Evp, CFO and Treasurer
    Feb 11, 2025 2,200 $101,200 37,513 (+5.9%) Grant
    Feb 7, 2025 4,040 $211,373 5,035 (+80.2%) Grant
    Feb 7, 2025 4,040 $211,373 33,627 (+12.0%) Grant
    Feb 7, 2025 4,040 $211,373 16,858 (+24.0%) Grant
    Feb 7, 2025 4,040 $211,373 4,040 (+100.0%) Grant
    Director
    Feb 7, 2025 4,040 $52,320 5,035 (+80.2%) Grant
    Feb 7, 2025 4,040 $211,373 10,109 (+40.0%) Grant
    Feb 7, 2025 5,168 $270,390 14,560 (+35.5%) Grant
    Vp, Chief Accounting Officer
    Feb 3, 2025 317 $16,791 9,603 (-3.3%) Sale
    SVP and General Manager, Genom
    Jan 31, 2025 417 $19,132 27,916 (+1.5%) Purchase
    Evp, CFO and Treasurer
    Dec 5, 2024 23,045 $1,037,025 29,545 (+78.0%) Grant
    Evp, CFO and Treasurer
    Dec 5, 2024 5,768 $259,560 35,313 (+16.3%) Grant
    SVP Gm, Sms
    Dec 4, 2024 140 $6,531 23,974 (-0.6%) Sale to Issuer
    Vp, Chief Accounting Officer
    Nov 19, 2024 163 $6,531 9,920 (-1.6%) Sale
    President and CEO
    Nov 19, 2024 1,250 $50,838 100,861 (+1.2%) Purchase
    Nov 19, 2024 4,940 $201,404 7,405 (+66.7%) Purchase
    SVP Gm, Sms
    Nov 19, 2024 348 $13,944 24,114 (-1.4%) Sale
    Svp, General Counsel, Secy.
    Nov 19, 2024 1,139 $45,640 112,564 (-1.0%) Sale
    SVP and Chro
    Nov 19, 2024 548 $21,958 19,373 (-2.8%) Sale
    Evp, Chief Financial Officer
    Nov 19, 2024 712 $28,530 23,892 (-3.0%) Sale
    SVP and General Manager, Genom
    Nov 19, 2024 491 $19,674 27,499 (-1.8%) Sale
    President and CEO
    Nov 18, 2024 12,716 $502,028 99,611 (+12.8%) Purchase
    Nov 18, 2024 12,500 $495,000 14,755 (+84.7%) Purchase
    Nov 18, 2024 1,000 $39,500 3,465 (+28.9%) Purchase
    Vp, Chief Accounting Officer
    Nov 15, 2024 6,921 $287,291 10,083 (+68.6%) Grant
    President and CEO
    Nov 15, 2024 83,622 $3,471,149 86,895 (+96.2%) Grant
    Svp, General Counsel, Secy.
    Nov 15, 2024 13,841 $574,540 113,703 (+12.2%) Grant
    SVP Gm, Sms
    Nov 15, 2024 8,651 $359,103 24,462 (+35.4%) Grant
    SVP and Chro
    Nov 15, 2024 10,381 $430,915 19,921 (+52.1%) Grant
    SVP and General Manager, Genom
    Nov 15, 2024 8,651 $359,103 27,990 (+30.9%) Grant
    Nov 6, 2024 995 $46,287 995 (-100.0%) Sale to Issuer
    Nov 6, 2024 995 $46,287 2,255 (-44.1%) Sale to Issuer
    Director
    Nov 6, 2024 995 $43,410 995 (+100.0%) Grant